Analysts See $0.71 EPS for Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Logo
Investors sentiment decreased to 1.06 in Q3 2018. Its down 0.24, from 1.3 in 2018Q2. It worsened, as 42 investors sold Vertex Pharmaceuticals Incorporated shares while 192 reduced holdings. 73 funds opened positions while 176 raised stakes. 231.66 million shares or 2.06% less from 236.55 million shares in 2018Q2 were reported.
Nordea Investment Mgmt Ab owns 0.01% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 13,830 shares. 3,025 were accumulated by Amer Natl Registered Inv Advisor. Peregrine Asset Advisers owns 13,562 shares for 1.18% of their portfolio. Hartford Mngmt has 28,371 shares. Moreover, Veritable L P has 0.03% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 7,293 shares. First Manhattan holds 825 shares or 0% of its portfolio. Riverhead Cap Management Llc holds 0.06% or 8,994 shares. Capstone Inv Advsrs Ltd Com invested in 0% or 1,902 shares. Brown Brothers Harriman & holds 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 372 shares. Bb&T Secs Limited Company holds 7,388 shares or 0.01% of its portfolio. Stratos Wealth Partners Limited stated it has 640 shares. Adage Ptnrs Gp Lc stated it has 0.17% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Cap Research Global Investors stated it has 0.15% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Regions Financial Corporation invested 0.01% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Arrow Fincl Corp has 0.01% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 330 shares.

Since July 16, 2018, it had 0 insider buys, and 20 sales for $8.50 million activity. Kewalramani Reshma also sold $430,920 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares. Another trade for 2,125 shares valued at $376,550 was sold by Parini Michael. ALTSHULER DAVID sold $715,893 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Friday, November 2. Shares for $4,749 were sold by Arbuckle Stuart A. $709,709 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by Sachdev Amit. Graney Thomas sold $207,926 worth of stock.

Analysts expect Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report $0.71 EPS on January, 30.They anticipate $0.39 EPS change or 121.88 % from last quarter’s $0.32 EPS. VRTX’s profit would be $181.45M giving it 64.89 P/E if the $0.71 EPS is correct. After having $0.76 EPS previously, Vertex Pharmaceuticals Incorporated’s analysts see -6.58 % EPS growth. The stock decreased 2.06% or $3.87 during the last trading session, reaching $184.29. About 827,109 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 25.22% since January 14, 2018 and is uptrending. It has outperformed by 25.22% the S&P500.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 8 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Vertex Pharmaceuticals had 13 analyst reports since July 26, 2018 according to SRatingsIntel. Citigroup maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, July 30 with “Buy” rating. H.C. Wainwright maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Wednesday, November 28 with “Buy” rating. BMO Capital Markets maintained the stock with “Outperform” rating in Thursday, October 25 report. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Outperform” rating given on Thursday, October 25 by Raymond James. The firm has “Neutral” rating by Guggenheim given on Tuesday, December 18. UBS maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Thursday, July 26. UBS has “Neutral” rating and $188 target. The firm earned “Buy” rating on Friday, October 26 by H.C. Wainwright. Morgan Stanley maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Wednesday, December 19. Morgan Stanley has “Overweight” rating and $210 target. On Friday, January 4 the stock rating was maintained by Citigroup with “Buy”. The rating was maintained by Morgan Stanley on Thursday, July 26 with “Overweight”.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $47.10 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 73.63 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Nasdaq.com which released: “July 6th Options Now Available For Vertex Pharmaceuticals (VRTX) – Nasdaq” on May 24, 2018, also Seekingalpha.com with their article: “Vertex Pharmaceuticals CFO bids adieu – Seeking Alpha” published on December 17, 2018, Seekingalpha.com published: “Vertex: Great Company But Too Pricey – Seeking Alpha” on October 29, 2018. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: 247Wallst.com and their article: “Major Biopharma Catalysts Coming in the First Quarter of 2019 – 24/7 Wall St.” published on January 07, 2019 as well as Benzinga.com‘s news article titled: “Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved – Benzinga” with publication date: December 18, 2018.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.